Diabetes PubMed

More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity.

Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing beta cells from endogenous progenitors.

Together with our previous report, we strongly suggest BBR as an ideal medicine for T2DM with a mechanism different from metformin and rosiglitazone.

The efficacy of the bark extract was comparable with Tolbutamide, a well-known hypoglycemic drug.

These results suggest that LSP1 and LSP2 show high potential to be explored as natural oral hypoglycemic agents.

Rimonabant improved glycemic control and cardiometabolic risk factors in patients with type 2 diabetes receiving insulin.

These results suggest that osthole can alleviate hyperglycemia and could be potentially developed into a novel drug for treatment of diabetes mellitus.

These results suggest that ADN gene therapy could be a clinically effective tool for the treatment of type 2 DM.

Compound 4x may serve as an interesting new compound for the development of therapeutics targeted against diet-induced hyperglycemia in diabetes.

Future development of this herb (Paeoniae Radix) as a dietary supplement or drug should bring substantial benefits for the diabetic population.